Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Multi-National, Multi-Centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multi-National, Multi-Centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-Based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Stallergenes Greer plc; Stallergenes SA
  • Most Recent Events

    • 07 Mar 2016 Pooled analysis of 4 trials (n=891), including this study and 3 other studies [see CTP 700020436, 700039691, 700040181] was presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 04 Jul 2012 Planned number of patients changed from 280 to 350 as reported by European Clinical Trials Database.
    • 17 Mar 2009 Status changed from recruiting to completed, based on reporting of results at AAAAI 2009.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top